Equity Details
Price & Market Data
Price: $19.25
Daily Change: +$0.05 / 0.26%
Daily Range: $18.68 - $19.49
Market Cap: $449,181,184
Daily Volume: 49,873
Performance Metrics
1 Week: -6.64%
1 Month: -22.38%
3 Months: -18.81%
6 Months: 9.94%
1 Year: 128.3%
YTD: -37.46%
About Lyell Immunopharma, Inc. (LYEL)
Detailed report on Lyell Immunopharma, Inc. (LYEL). Current price: 19.25, daily change: +$0.05 / 0.26%. Market cap: 449,181,184. Explore all performance metrics.
Company Details
Employees: 161
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.